NMN vs CoQ10: Which One Has the Better Evidence?

The two molecules are not doing the same job

CoQ10 carries electrons between complexes I, II and III of the electron transport chain. It is the shuttle. NAD+, which NMN feeds, is what delivers electrons into complex I in the first place. It is the delivery van.

So the question is not which one makes more energy. Both are needed, and a healthy cell runs out of neither. The question is which one, taken as a capsule, changes anything measurable in a person who is not deficient.

On that question the two have very different answers. One has a modest but repeatable effect. The other has a much thinner file.

CoQ10 and fatigue: a real effect, and a small one

Thirteen randomised trials, 1,126 participants, pooled in 2022. Fatigue scores fell against placebo by Hedges' g = -0.398, with a 95% confidence interval of -0.641 to -0.155.

That is a small-to-moderate effect. In plain terms, roughly a third of a standard deviation on a fatigue questionnaire. Not nothing, and not the transformation the packaging implies.

Two details matter more than the headline. The direction was the same in healthy participants and in patients, which argues against it being a sick-people-only finding. And the effect was significant when CoQ10 was given alone, but not when it was buried inside a multi-ingredient compound.

If you buy a blend where CoQ10 is one of nine things on the label, you are buying the arm of the analysis that did not work.

The muscle damage numbers are the more interesting ones

For someone training four or five times a week, fatigue questionnaires are the wrong outcome. Blood markers after hard sessions are closer to the point.

A 2024 dose-response meta-analysis pooled 28 trials in 830 adults. Creatine kinase fell by 50.6 IU/L against placebo. Lactate dehydrogenase fell by 52.1 IU/L. Myoglobin fell by 21.8 ng/ml. Malondialdehyde, a lipid oxidation marker, fell by 0.73 micromol/l.

There was a gradient. Each additional 100 mg a day was associated with a further 23.1 IU/L fall in creatine kinase.

Two caveats, both real. Most of these trials were run in Asia, which the authors flag as a limit on generalisability. And lower creatine kinase is a marker of less muscle disruption, not proof you will recover faster or train better. Nobody has shown the second thing follows from the first.

NMN's file is thinner than its marketing

Ten randomised trials, 437 participants, mean age 58, average follow-up 9.6 weeks, doses from 150 to 1,200 mg a day. Mean grip strength went from 29.9 kg to 30.5 kg. Skeletal mass index went from 7.4 kg/m2 to 7.4 kg/m2.

The review's own conclusion was that physical performance improved non-significantly. That is an honest way of saying it did not improve.

The metabolic picture is the same shape. Eight trials, 342 middle-aged and older adults, 250 to 2,000 mg a day for 14 days to 12 weeks. No significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR or any lipid measure.

NMN does raise blood NAD+. That part is settled and dose-dependent. What has not been shown is that raising it changes an outcome you can feel.

Where NMN has produced something

One trial is the exception, and it is the one worth knowing. Forty-eight amateur runners, aged 27 to 50, took 300, 600 or 1,200 mg a day for six weeks while training five or six times a week.

VO2 max did not move. Neither did peak power or O2 pulse. What rose was oxygen uptake and power at the ventilatory thresholds, and it rose with the dose.

Oxygen uptake at the first ventilatory threshold, expressed as a percentage of VO2 max, went up 2.1 points on placebo and 10.3 points on 1,200 mg. The authors read this as better oxygen use by muscle rather than any change in the heart.

Twelve people per arm. Six weeks. One site. Treat it as a promising signal, not a settled finding, and note that no one has replicated it.

A second trial points the same way, more weakly. Eighty healthy adults aged 40 to 65 took placebo, 300, 600 or 900 mg a day for 60 days. Blood NAD+ rose dose-dependently. Six-minute walk distance improved significantly in the 300 mg and 600 mg groups.

A six-minute walk test is a clinical measure of function, not an athletic one. In a group that trains four times a week it is close to a ceiling already. So read that result as evidence NMN can move something, not as evidence it will move something in you.

Neither is allowed to claim an energy benefit in the UK

This is the part the category tends to skip. EFSA assessed CoQ10 in 2010 against Article 13(1) of Regulation (EC) 1924/2006, covering energy-yielding metabolism, blood pressure, protection from oxidative damage, cognitive function, cholesterol and endurance performance.

None of it was substantiated. No health claim for CoQ10 is authorised on the GB register. So any UK seller telling you their CoQ10 boosts your energy is making a claim regulators have already looked at and refused.

NMN sits further back. Its novel food application, RP-2116, is on the FSA register at the risk assessment phase. We wrote about how that process works in our guide to novel foods in Great Britain.

What follows from this is simple. Judge both on trial data, because the label is not allowed to tell you anything useful.

What we would actually do with this

If your problem is fatigue, the CoQ10 evidence is the better bet. It is a small effect from a large pool, the dose gradient points upward, and single-ingredient products outperformed blends. Buy it on its own or not at all.

If your problem is threshold performance and you are already training hard, NMN has one trial in your direction and a lot of flat results elsewhere. That is a punt, and it should be priced as one. If you take it, take a declared dose from a product that publishes its certificate of analysis, so at least the input to your experiment is known.

If your problem is neither, and you were hoping one of these would make you feel different day to day, the honest answer is that the trials do not support that expectation for either molecule. Sleep, training load and iron status will move that needle further than a capsule. Our guide to NMN dosage sets out what the trials used if you decide to run the experiment anyway.

How to test either one on yourself

Pick one. Running both at once means you learn nothing about either.

Pick an outcome you already measure. Threshold power, a fixed running route, session RPE across a training week, or a fatigue score you record the same way each Sunday. Feelings are not data at this effect size.

Give it eight to twelve weeks. The fatigue meta-regression found longer treatment produced larger effects, and the NMN trials ran 14 days to 12 weeks. Anything shorter cannot distinguish a real change from a good fortnight.

Then be willing to stop. A supplement that has not moved your number in three months has told you its answer, and the answer for most people, most of the time, is no.

The short version

CoQ10 has more people behind it, an older literature, and a small but consistent effect on fatigue that survives sensitivity analysis. Its ceiling is modest.

NMN raises NAD+ reliably and has yet to convert that into a functional outcome outside one 48-person trial. Its ceiling is unknown, which is different from being high.

Neither is authorised to say any of this on a label in Great Britain. Both are safe at the doses studied. If you want the better-evidenced option today, that is CoQ10, on its own, at the higher end of the tested range.

References

1. Tsai, I.C., Hsu, C.W., Chang, C.H., Tseng, P.T., Chang, K.V. (2022). "Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Frontiers in Pharmacology, 13, 883251. PMID 36091835. DOI 10.3389/fphar.2022.883251.
2. Talebi, S., Pourgharib Shahi, M.H., Zeraattalab-Motlagh, S., et al. (2024). "The effects of coenzyme Q10 supplementation on biomarkers of exercise-induced muscle damage, physical performance, and oxidative stress: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials." Clinical Nutrition ESPEN, 60, 122-134. PMID 38479900. DOI 10.1016/j.clnesp.2024.01.015.
3. Pai, D. (2024). "Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials." Cureus, 16(8), e65961. DOI 10.7759/cureus.65961.
4. Chen, F., Zhou, D., Kong, A.P.S., Yim, N.T., Dai, S., Chen, Y.N., Hui, L.L. (2024). "Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials." Current Diabetes Reports, 25(1), 5. PMID 39531138. DOI 10.1007/s11892-024-01557-z.
5. Liao, B., Zhao, Y., Wang, D., Zhang, X., Hao, X., Hu, M. (2021). "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition, 18(1), 54. PMID 34238308. DOI 10.1186/s12970-021-00442-4.
6. Yi, L., Maier, A.B., Tao, R., et al. (2023). "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, 45(1), 29-43. DOI 10.1007/s11357-022-00705-1.
7. EFSA Panel on Dietetic Products, Nutrition and Allergies (2010). "Scientific Opinion on the substantiation of health claims related to coenzyme Q10 and contribution to normal energy-yielding metabolism (ID 1508, 1512, 1720, 1912, 4668) ... and increase in endurance capacity and/or endurance performance (ID 1913) pursuant to Article 13(1) of Regulation (EC) No 1924/2006." EFSA Journal, 8(10), 1793. DOI 10.2903/j.efsa.2010.1793.
8. Food Standards Agency (2026). "Register of regulated product applications: RP-2116, beta-Nicotinamide Mononucleotide." Novel foods application, phase: risk assessment.

If you pick NMN, pick one with a dose you can check

Our NMN + Resveratrol declares 500 mg of NMN and 600 mg of trans-resveratrol per serving, with a batch certificate of analysis published for every run. The evidence is thinner than the marketing suggests, and we would rather you knew that before you bought anything.

See the Label and the CoA →